|
Federal Register
Notices > Importers >
Cerilliant Corporation
FR Doc E6-18253 [Federal Register: October 31, 2006 (Volume 71, Number 210)]
[Notices] [Page 63781] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr31oc06-72]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a
registration under this Section to a bulk manufacturer of a controlled substance
in schedule I or II and prior to issuing a regulation under 21
U.S.C.
952(a)(2)(B) authorizing the importation of such a substance, provide
manufacturers holding registrations for the bulk manufacture of the substance an
opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on July
19, 2006, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas
78664, made application by renewal to the Drug Enforcement Administration (DEA)
to be registered as an importer of the basic classes of controlled substances
listed in schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
|
Ibogaine (7260)
|
I
|
|
Alpha-methyltryptamine (7432)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine(7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
Etorphine (except HCI) (9056)
|
I
|
|
Heroin (9200)
|
I
|
|
Pholcodine (9314)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Methylphenidate (1724)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (2270)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Dextropropoxyphene bulk (non-dosage form)(9273) |
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Levo-alphacetylmethadol (9648)
|
II
|
|
Oxymorphone (9652)
|
II
|
The company plans to import small quantities of the listed controlled
substances for the manufacture of analytical reference standards.
Any manufacturer who is presently, or is applying to be, registered with DEA
to manufacture such basic classes of controlled substances may file comments or
objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal Register
Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301;
and must be filed no later than November 30, 2006.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a
previous notice published in the Federal Register on September 23, 1975, (40 FR
43745-46), all applicants for registration to import a basic class of any
controlled substance listed in schedule I or II are, and will continue to be
required to demonstrate to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21
U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: October 24, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-18253 Filed 10-30-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|